Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.

Employees

Sector

Pharmaceuticals

More about the company

04-29	SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-28	SciSparc Ltd. Auditor Raises 'Going Concern' Doubt	CI

Market Cap	2.69M 809M 2.36M 2.18M 2.01M 3.81M 257M 3.88M 26M 10.2M 127M 10.11M 9.9M 436M	P/E 2024	-0.33x	P/E 2025	-0.12x
Enterprise Value	-1.53M -460M -1.34M -1.24M -1.14M -2.17M -146M -2.2M -14.77M -5.79M -71.91M -5.75M -5.62M -247M	EV / Sales 2024	-551,308x	EV / Sales 2025	289,759x
Free-Float	100%	Yield 2024 *	-	Yield 2025	-

04-29	SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-28	SciSparc Ltd. Auditor Raises 'Going Concern' Doubt	CI
03-16	Neurothera Labs Inc. Clearmind Medicine Inc. Collaboration Leads to Patent Application for Depression Therapy	CI
03-16	Scisparc Neurothera Labs- Clearmind Medicine collaboration leads to patent application for depression therapy	RE
03-10	Clearmind Medicine Inc Announces Publication of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Metabolic Dysfunction-Associated Steatotic Liver Disease	CI
03-10	Top Premarket Decliners	MT
02-11	SciSparc Ltd. announced that it expects to receive $9 million in funding	CI
01-25	Neurothera Labs Inc. completed the acquisition of Portfolio of patents, trademarks, know-how of Xylo Technologies Ltd.	CI
01-13	SciSparc Subsidiary to Acquire Endoscopic Patents of Xylo Technologies in All-Stock Deal	MT
12-30	SciSparc Ltd.'s Equity Buyback announced on July 7, 2022, has expired.	CI
12-01	Scisparc plans on entering the multi-billion-dollar GERD device market with acquisition of an approved IP portfolio	RE
11-26	Scisparc to acquire treasury of patents for innovative medical endoscopy systems	RE
11-26	Scisparc shares climb 27.5% premarket; co says will buy a treasury of patents, trademarks and intellectual property rights from Xylo	RE

06-05	SciSparc, Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum	AQ
06-04	SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum	GL
05-28	SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum	GL
04-22	AI Power Bottleneck Sparks Opportunity: Sphere 3D Corp. (NASDAQ: ANY) Emerging as Data Center Infrastructure Play	AQ
03-16	Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy	AQ

Manager	Title	Age	Since
Oz Adler CEO	Chief Executive Officer	39	2022-01-09
Amitay Weiss CEO	Chief Executive Officer	62	2020-08-20
Adi Zuloff-Shani CTO	Chief Tech/Sci/R&D Officer	56	2016-02-07

Therapix Biosciences Ltd Stock TEL AVIV STOCK EXCHANGE

Stocks

IL0010951403

Pharmaceuticals

Valuation: Therapix Biosciences Ltd

Latest news : Therapix Biosciences Ltd

Press Releases: Therapix Biosciences Ltd

News in other languages: Therapix Biosciences Ltd

Managers and Directors: Therapix Biosciences Ltd

Generic Pharmaceuticals

Financials

Company Profile

End-of-day quote TEL AVIV STOCK EXCHANGE Other stock markets
- ^ILa	-

Director	Title	Age	Since
Amitay Weiss CHM	Chairman	62	2022-01-09
Itschak Shrem CHM	Chairman	79	2025-09-20
Lior Vider BRD	Director/Board Member	50	2020-08-20

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.17%	+3.45%	+15.94%	+86.88%	48.73B
OTSUKA HOLDINGS CO., LTD.	+1.04%	-3.54%	+67.29%	+114.44%	35.82B
CIPLA LIMITED	-0.13%	-1.14%	-3.51%	+41.03%	12.2B
ZYDUS LIFESCIENCES LIMITED	-0.71%	+4.64%	+17.61%	+97.65%	12.11B
KRKA, D. D.	-0.76%	+1.75%	+34.02%	+123.93%	9.11B
ONO PHARMACEUTICAL CO., LTD.	-0.86%	+1.08%	+53.57%	-3.92%	7.09B
GEDEON RICHTER	+0.75%	-0.17%	+17.95%	+45.66%	7B
GLENMARK PHARMACEUTICALS LIMITED	+0.69%	+3.96%	+25.52%	+231.22%	6.7B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+5.45%	+1.89%	-18.02%	+13.55%	5.78B
Average	+0.59%	+0.30%	+23.38%	+83.38%	16.06B
Weighted average by Cap.	+0.33%	+0.51%	+29.33%	+90.39%

	2024	2025
Net sales	1.31 392.14 1.14 1.05 0.97 1.85 124.55 1.88 12.6 4.94 61.35 4.9 4.8 211.14	0.86 257.02 0.75 0.69 0.64 1.21 81.64 1.23 8.26 3.24 40.21 3.21 3.14 138.39
Net income	-6.28M -1.89B -5.51M -5.08M -4.69M -8.89M -599M -9.04M -60.64M -23.79M -295M -23.59M -23.08M -1.02B	-12.18M -3.66B -10.67M -9.84M -9.09M -17.24M -1.16B -17.52M -118M -46.1M -572M -45.72M -44.73M -1.97B
Net Debt	-2.01M -604M -1.76M -1.62M -1.5M -2.85M -192M -2.89M -19.41M -7.61M -94.47M -7.55M -7.39M -325M	-4.22M -1.27B -3.7M -3.41M -3.15M -5.98M -403M -6.08M -40.77M -15.99M -198M -15.86M -15.52M -683M